Management And Risk Prediction Of Paracetamol Overdose
Funder
National Health and Medical Research Council
Funding Amount
$98,950.00
Summary
Paracetamol overdose is the most common pharmaceutical poisoning in developed countries and incidence is increasing in the developing world. Overdose can lead to liver failure and death. Our research will evaluate a novel antidote regimen and whether early cessation of antidote for paracetamol toxicity in a specific cohort is safe, with implications of decreasing time in hospital. We will also identify risk prediction tools to help early identification of patients needing intensive treatment
Worldwide >360 million people have chronic hepatitis B virus (HBV) infection that imparts a 25% lifetime risk of death due to serious liver disease. Current therapies for chronic HBV reduce levels of virus replication but fail to target the stable, nuclear episome, covalently closed circular DNA (cccDNA). The current study will determine what is required to eliminate cccDNA and how current therapies for chronic HBV infection should be modified to achieve this aim.
Identification Of Cardiac Sarcoplasmic Reticulum Targets For Cardiotoxic Drugs
Funder
National Health and Medical Research Council
Funding Amount
$265,986.00
Summary
Anthracyclines are drugs which are used successfully in chemotherapy. Unfortunately, these drugs can lead to serious heart problems which sometimes result in death, and the mechanisms behind this remain elusive. Finding the specific targets of these drugs and how these drugs affect heart contraction may lead to designing drug cocktails which protect the heart from side effects.
Effects Of Ageing On Hepatic Drug Clearance And Mechanisms Of Drug Induced Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$581,892.00
Summary
With increasing age, there is increase in disease, for which medications may provide benefit, and an increase in the risk of adverse drug reactions, even after considering the increase in medication use by older people. We will investigate how the liver clears drugs from the blood in old age. This will guide dosing of medications for older people. We will also study how drugs injure the liver in old age and test interventions to prevent this toxicity.
SULT4A1 is not a sulfotransferase, but a sulfotransferase inhibitor. It forms high affinity heterodimers with other sulfotransferases via a conserved dimerisation site in its carboxyl terminus attenuating catalytic activity. Consequently, it is important for the metabolism of numerous important molecules including estrogens, thyroid hormones, neurotransmitters and many therapeutic agents.
Pesonalised Risk Prediction For Severe Treatment-related Gastrointestinal Toxicity In Paediatric Cancer Patients Using Pre-treatment Gut Microbiome Analysis
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
The gut is home to trillions of good and bad bacteria, critical to human health. Each person has a different balance of bacteria, unique to their gut, which shapes their immune system and susceptibility to disease. I will investigate how the unique gut bacteria, in children with blood cancer, can be used to predict which children will develop severe gut side effects (diarrhoea) from their chemotherapy. This will identify high-risk children, enable personalised treatment and improve survival.
Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Evaluation Of The Safety Of Lead Compounds For Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$310,568.00
Summary
Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.